- Home
- JSPR vs ANL Comparison
JSPR vs ANL Comparison
Compare JSPR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JSPR | ANL |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | JSPR | ANL |
|---|---|---|
| Price | $1.81 | $1.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $25.60 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 26.4K |
| Earning Date | 11-10-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $0.88 |
| 52 Week High | $23.11 | $2.99 |
Technical Indicators
Market Signals| Indicator | JSPR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 51.04 |
| Support Level | $1.60 | $0.88 |
| Resistance Level | $1.93 | $1.59 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 36.90 | 70.48 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.